OMER - Omeros Corporation
14.79 +0.14 (0.98%)
After hours: 4:11PM EDT
| Previous Close | 15.49 |
| Open | 15.42 |
| Bid | 14.64 x 1000 |
| Ask | 14.80 x 1100 |
| Day's Range | 14.58 - 15.42 |
| 52 Week Range | 10.30 - 27.00 |
| Volume | 654,117 |
| Avg. Volume | 393,429 |
| Market Cap | 718.698M |
| Beta (3Y Monthly) | 2.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.48 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.20 |
- Schaeffer's Investment Research•8 days ago
Calls Pop as Drug Stock Gets FDA Boost
OMER options are seeing heavy trading today
- Benzinga•8 days ago
Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment
Omeros announced Thursday ahead of the market open that it has reached an agreement with the FDA on the response-based primary endpoint of its pivotal trial to support the biologic license application for narsoplimab. Narosoplimab, codenamed OMS721, is Omeros' lead human monoclonal antibody candidate for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HSCT-TMA. Omeros said it will now complete the ongoing data collection from medical records of patients already treated with narosplimab either in the clinical trial or under compassionate use for inclusion in the clinical sections of the BLA.
- Business Wire•8 days ago
Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA
Omeros Corporation today announced agreement with the U.S. Food and Drug Administration (FDA) on the response-based primary endpoint for its pivotal trial to support the biologics license application (BLA) for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab, also known as “OMS721,” is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). There is no approved product for the treatment or prevention of HSCT-TMA, and narsoplimab is the only drug in development for the treatment of HSCT-TMA to be granted FDA’s breakthrough therapy designation.
- Thomson Reuters StreetEvents•last month
Edited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Omeros Corp Earnings Call
- Business Wire•last month
Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
Omeros Corporation (OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application (MAA) currently in preparation for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab, also known as “OMS721,” is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) and is in Phase 3 clinical programs for the treatment of HSCT-TMA, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome.
- Simply Wall St.•2 months ago
Is Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate?
In 1994 Gregory Demopulos was appointed CEO of Omeros Corporation (NASDAQ:OMER). First, this article will compare CEO...
- Business Wire•2 months ago
Omeros to Present at the UBS Global Healthcare Conference
Omeros Corporation today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week.
Motley Fool•2 months agoOmeros (OMER) Q1 2019 Earnings Call Transcript
OMER earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
Omeros (OMER) delivered earnings and revenue surprises of -11.76% and -4.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Omeros: 1Q Earnings Snapshot
The Seattle-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs, came to 38 cents per share. The drug developer posted revenue of $21.8 million in the period. ...
- Business Wire•2 months ago
Omeros Corporation Reports First Quarter 2019 Financial Results
– Conference Call Today at 4:30 p.m. ET –
- Insider Monkey•2 months ago
Did Hedge Funds Drop The Ball On Omeros Corporation (OMER) ?
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]
- Business Wire•2 months ago
Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
- Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids-
- Business Wire•2 months ago
Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
Omeros Corporation (OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally.
- Zacks•3 months ago
Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•3 months ago
Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
Omeros Corporation today announced that the results of an investigator-sponsored real-world study of its FDA-approved ophthalmic drug OMIDRIA® 1% / 0.3% will be presented at the American Society of Cataract and Refractive Surgery – American Society of Ophthalmic Administrators Annual Meeting to be held in San Diego May 3-7, 2019.
- Business Wire•4 months ago
Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
Omeros Corporation (OMER) today announced the recent presentation of a case report describing resolution of gastrointestinal hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) following narsoplimab treatment under a compassionate-use protocol. The case was presented at the 2019 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) held March 24-27 in Frankfurt, Germany. Omeros is reporting the case to ensure broad availability of the information presented.
- Business Wire•4 months ago
Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
Omeros Corporation (OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Marrow Transplantation to be held in Frankfurt, Germany on March 24-27, 2019. Sponsored by Omeros, the educational session entitled “How Do I … Diagnose HSCT-TMA” will be held on Tuesday, March 26, at 2:00-3:30 PM local time. There is growing recognition that hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a potentially lethal complication of stem-cell transplants, is underdiagnosed in the U.S. and worldwide.
- Zacks•4 months ago
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of OMER earnings conference call or presentation 1-Mar-19 1:30pm GMT
Q4 2018 Omeros Corp Earnings Call
- Business Wire•5 months ago
Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
– Conference Call Today at 8:30 a.m. ET –
- Business Wire•5 months ago
Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
Omeros Corporation (OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.
- GlobeNewswire•5 months ago
Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•5 months ago
Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
Omeros Corporation today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names Council, in consultation with the World Health Organization’s International Nonproprietary Names Expert Committee, has selected for the drug the nonproprietary name “narsoplimab.” Narsoplimab is the company’s lead human monoclonal antibody targeting mannan-binding ...
- Motley Fool•5 months ago
Why Omeros Stock Jumped Today
The small biotech received good news from the FDA.
